STAT

Alexion’s newly approved rare-disease drug notches another clinical trial win

Alexion's newly approved rare-disease drug notches another clinical trial win — this time in patients with a rare type of kidney disease.
Source: Kristoffer Tripplaar/SIPA/AP

Alexion Pharmaceuticals (ALXN) said Monday that its newly approved drug Ultomiris achieved the primary goal of a late-stage clinical trial involving patients with a rare type of kidney disease.

Based on the successful outcome of the clinical trial,

You're reading a preview, sign up to read more.

More from STAT

STAT3 min read
FDA Slams Dollar Tree For Purchasing Drugs From Suppliers With Checkered Safety Records
Dollar Tree purchased drugs from foreign companies that failed to follow manufacturing standard, displaying a pattern of serious violations, the FDA said in a warning letter.
STAT4 min read
Opinion: President Trump: Don’t Fail America’s Children On Flavored E-cigarettes
If flavors are the bait that attracts kids to e-cigarettes, nicotine is the hook. Some of the most popular e-cigarettes contain as much nicotine as a pack of cigarettes.
STAT7 min read
In France, It’s Illegal For Consumers To Order A DNA Spit Kit. Activists Are Fighting Over Lifting The Ban
Under French law, having a direct-to-consumer genetic test can, technically speaking, put you at risk of being fined about $4,140.